Treatment of Early-Stage p16 (HPV)-Positive Squamous Cell Carcinoma of the Tonsil (Oropharynx)
This protocol addresses patients with squamous cell carcinoma of the tonsil in the oropharynx whose tumor is confirmed p16 (HPV)-positive and presents at an early clinical stage — a sub-population with distinct management considerations.
- Primary site: tonsil, oropharynx — squamous cell carcinoma
- HPV status: p16-positive (confirmed by IHC)
- Early clinical stage: T1–2, N0 — or T0–2, N1 with a single node ≤ 3 cm
p16 immunohistochemistry (IHC) testing of the tumor is required to confirm eligibility for this sub-population.
Single-modality treatment targeting both the primary tumor and the neck is the foundation of management for this early-stage, HPV-positive presentation. Approaches include surgical and radiotherapeutic options, with combined-modality strategies considered in certain node-positive cases; clinical trial enrollment is also an option.
Complete treatment selection, sequencing, dosing framework, and eligibility criteria are detailed in the full structured protocol.
References
- Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate
- Tumor human papillomavirus (HPV) testing by p16 IHC required
- p16 (HPV)-positive
- T1–2, N0
- T0–2, N1 (single node ≤3 cm)
- Resection of primary and ipsilateral or bilateral selective neck dissection
- Definitive RT
- Concurrent systemic therapy/RT (category 2B)
- Clinical trials